Verona

Frazier Life Sciences nets $1.1B in long-running biotech fund

Frazier Life Sciences (FLS) has stacked up another sizable biotech-focused capital commitment, netting more than $1.1 billion for its long-running public fund.

Will Maddox Sep 10, 2026 9:44am

Verona's COPD drug hits goal in phase 3, teeing up FDA filing

Aug 9, 2022 6:40am

Frontier launches with biotech vet CEO—Chutes & Ladders

Jun 28, 2019 9:30am

Verona hires ex-GSK researchers for late-phase push in COPD

Jun 25, 2019 8:10am

Verona tanks after COPD drug misses phase 2 endpoint

Jan 14, 2019 9:25am

Verona jumps as midphase cystic fibrosis data dial up hopes

Mar 2, 2018 9:25am